Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

Design and rationale of two phase 3 randomised controlled trials (COUGH-1 and COUGH-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough

Background We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods COUGH-1 (NCT03449134) and COUGH-2 (NCT03449147) are ra...

Full description

Bibliographic Details
Main Authors: David R. Muccino, Alyn H. Morice, Surinder S. Birring, Peter V. Dicpinigaitis, Ian D. Pavord, Christopher Assaid, Huub Jan Kleijn, Azher Hussain, Carmen La Rosa, Lorcan McGarvey, Jaclyn A. Smith
Format: Article
Language:English
Published: European Respiratory Society 2020-11-01
Series:ERJ Open Research
Online Access:http://openres.ersjournals.com/content/6/4/00284-2020.full

Internet

http://openres.ersjournals.com/content/6/4/00284-2020.full

Similar Items